Kymera Therapeutics (KYMR) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Kymera Therapeutics (NASDAQ: KYMR):

• 11/2/2026 – Kymera Therapeutics had its price target raised by Barclays from $139.00 to $170.00. They now have an “overweight” rating on the stock.
• 10/31/2026 – Kymera Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 10/30/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by Truist Financial. They now have a $150.00 price target on the stock, up from $136.00.
• 10/30/2026 – Kymera Therapeutics had its price target raised by Royal Bank Of Canada from $112.00 to $116.00. They now have a “sector perform” rating on the stock.
• 10/29/2026 – Kymera Therapeutics had its “outperform” rating reaffirmed by Oppenheimer. They now have a $140.00 price target on the stock.
• 10/29/2026 – Kymera Therapeutics was given a new $132.00 price target by Loop Capital.
• 10/29/2026 – Kymera Therapeutics had its “buy” rating reaffirmed by Brookline Capital Markets.
• 10/29/2026 – Kymera Therapeutics had its “outperform” rating reaffirmed by Raymond James Financial.
• 10/29/2026 – Kymera Therapeutics had its price target raised by BTIG Research from $134.00 to $139.00. They now have a “buy” rating on the stock.
• 10/27/2026 – Kymera Therapeutics had its price target raised by Morgan Stanley from $135.00 to $146.00. They now have an “overweight” rating on the stock.
• 10/15/2026 – Kymera Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/8/2026 – Kymera Therapeutics is now covered by Raymond James Financial. They set an “outperform” rating and a $140.00 price target on the stock.
• 10/8/2026 – Kymera Therapeutics is now covered by Raymond James Financial. They set an “outperform” rating and a $140.00 price target on the stock.
• 10/5/2026 – Kymera Therapeutics had its price target raised by Citigroup from $135.00 to $150.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Kymera Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $140.00 price target on the stock.
• 9/22/2026 – Kymera Therapeutics had its price target raised by Stifel Nicolaus from $132.00 to $152.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Kymera Therapeutics had its price target raised by Bank of America from $123.00 to $144.00. They now have a “buy” rating on the stock.

Kymera Therapeutics Trading Down 1.6%

Shares of NASDAQ KYMR opened at $136.64 on Wednesday. The stock has a market capitalization of $11.66 billion, a PE ratio of -37.75 and a beta of 2.04. The stock has a fifty day simple moving average of $116.45 and a 200-day simple moving average of $98.47. Kymera Therapeutics, Inc. has a twelve month low of $60.25 and a twelve month high of $142.92.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06). The business had revenue of $1.35 million for the quarter, compared to analyst estimates of $3.28 million. Kymera Therapeutics had a negative return on equity of 22.39% and a negative net margin of 285.33%. The firm’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.94) EPS. On average, equities analysts predict that Kymera Therapeutics, Inc. will post -3.88 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Brian Adams sold 6,371 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. This represents a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the completion of the sale, the chief executive officer owned 666,568 shares in the company, valued at $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 15.98% of the stock is currently owned by corporate insiders.

Kymera Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines that selectively remove disease-causing proteins from cells. Its approach, known as targeted protein degradation, uses the body’s natural protein-disposal system and is designed to address targets that may be difficult to reach with conventional drugs. The company’s research and development programs include small-molecule protein degraders for conditions involving immune and inflammatory pathways, as well as cancer.